Previous studies suggested that early pregnancy exposure to specific oral decongestants increases the risks of several birth defects. Using January 1993-January 2010 data from the Slone Epidemiology Center Birth Defects Study, we tested those hypotheses among 12,734 infants with malformations (cases) and 7,606 nonmalformed control infants in the United States and Canada. Adjusted odds ratios and 95% confidence intervals were estimated for specific birth defects, with controlling for potential confounders. Findings did not replicate several hypotheses but did support 3 previously reported associations: phenylephrine and endocardial cushion defect (odds ratio = 8.0; 95% confidence interval: 2.5, 25.3; 4 exposed cases), phenylpropanolamine and ear defects (odds ratio = 7.8; 95% confidence interval: 2.2, 27.2; 4 exposed cases), and phenylpropanolamine and pyloric stenosis (odds ratio = 3.2; 95% confidence interval: 1.1, 8.8; 6 exposed cases). Hypothesis-generating analyses involving multiple comparisons identified a small number of associations with oral and intranasal decongestants. Accumulating evidence supports associations between first-trimester use of specific oral and possibly intranasal decongestants and the risk of some infrequent specific birth defects. birth defects; decongestants; maternal exposure; pregnancy Abbreviations: BDS, Slone Epidemiology Center Birth Defects Study; CI, confidence interval; OR, odds ratio; OTC, over-thecounter.
Decongestants, particularly pseudoephedrine, are among the over-the-counter (OTC) medications most commonly used during pregnancy (1) . Because they are available without prescription, they are widely perceived as safe by healthcare providers and pregnant women, yet the safety of prenatal exposure with regard to specific birth defects remains unclear. Given their extensive use, even a small increase in the risk of birth defects would have considerable public health implications.
All decongestants are vasoconstrictive and could share class-related effects. On the other hand, teratogenicity can vary within a given class (2) , which makes it necessary that consideration also be given to specific decongestants. Epidemiologic studies of specific decongestants have identified elevated risks of specific birth defects, including defects of the heart, eyes and ears, gut, abdominal wall, and feet (Web Table 1 , available at http://aje.oxfordjournals.org/) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) .
Using data from the Slone Epidemiology Center Birth Defects Study (BDS), we tested the previously reported associations between specific birth defects and first-trimester exposure to oral decongestants and, in hypothesis-generation analyses, explored the risks of other common major congenital malformations. In addition, we explored the risk of specific birth defects in relation to first-trimester use of intranasal decongestants.
MATERIALS AND METHODS

Study population
The BDS was initiated in 1976 as a case-control surveillance program of birth defects in relation to medications. Details of the methods have been described (17, 18) . The present analysis was based on data from subjects interviewed between January 1993 and January 2010. During those years, study nurses interviewed women within 6 months of delivery who had malformed infants or fetuses identified at regional centers around Boston, Massachusetts; Philadelphia, Pennsylvania; Toronto, Ontario; and San Diego, California; as well as from birth defects registries in Massachusetts and New York State. Mothers of nonmalformed (control) infants were identified at participating birth hospitals and from a population-based sample of nonmalformed infants in Massachusetts. Between January 1993 and June 1998, mothers of 3,723 cases and 781 controls were interviewed in person ("phase 1"), and between August 1998 and January 2010, mothers of 12,746 cases and 6,826 controls were interviewed by telephone ("phase 2"). Overall, among mothers of eligible cases and controls who could be contacted, the proportions who completed the interview were 69% and 67%, respectively (Web Figure) . The study was approved by the institutional review boards at relevant institutions, and is compliant with requirements of the Health Insurance Portability and Accountability Act.
Cases and controls
Cases eligible for final analyses consisted of 12,734 infants and fetuses with a confirmed diagnosis of major congenital malformation(s), identified up to a minimum of 3 and a maximum of 5 months after delivery. Infants with chromosomal defects, known Mendelian inherited disorders, syndromes, DiGeorge sequence (associated with 22q deletion), and defects associated with prematurity were excluded. Cases with multiple anomalies were considered in each appropriate defect category. Controls eligible for final analyses consisted of 7,606 nonmalformed infants.
Exposure ascertainment
Subjects who provided informed consent for interview were asked to provide a release for their infant's medical record. Using highly structured interview procedures and questionnaires, trained study nurses interviewed mothers within 6 months of delivery. Information was sought about demographic characteristics; reproductive, medical, and lifestyle factors; diet; and details of exposures to all medications ( prescription and OTC) at any time from 56 days before the date of the last menstrual period through the end of pregnancy. Mothers and study nurses were unaware of the various hypotheses under consideration.
To maximize recall of medication exposures and minimize errors in reported exposures, highly structured questionnaires included a series of increasingly detailed questions (19) . Interviewers first asked about the occurrence of any of a list of illnesses (e.g., infections) during pregnancy and the medications taken for those illnesses, then about use of categories of medications (e.g., antibiotics, nasal sprays), and finally about use of specific products, including brand and generic names. Mothers who reported taking a medication were asked to identify the dates when use began and ended; recall was enhanced by a calendar highlighting key dates and events (e.g., last menstrual period, Christmas, delivery date). Subjects were also asked about the medication's dose and form and the frequency and duration of use. A Medication Identification Booklet with photographs of specific OTC medications was used to enhance recall of OTC products. All medications were coded via the Slone Drug Dictionary, which links each product to its individual active ingredients. Changes in product formulations over time are incorporated in the Drug Dictionary, and new formulations are coded accordingly.
Exposure definition and classification
The date of the last menstrual period was based on early ultrasound examination or maternal recall. We defined the estimated date of conception as 14 days after the date of the last menstrual period, the first trimester as 90 days after the estimated date of conception (encompassing the etiologically important period of structural development for most organs), the second trimester as 90 days after the first trimester, and the third trimester as the period after the second trimester through the end of pregnancy. We considered exposure in any given trimester to include maternal use of a decongestant on at least 1 day.
Using our exposure classification algorithm (20) , which considers recall uncertainty in timing of medication exposure on the basis of the subject's self-reported precision of the start/stop dates and duration of use, we classified decongestant exposure into the following categories: "unexposed at any time from 56 days before the last menstrual period date through the end of pregnancy"; "likely exposed" and "possibly exposed" in a given trimester; and "exposed only outside a given trimester." For each specific decongestant, our exposure group of primary interest was subjects classified as "likely exposed" to only the specific decongestant, without exposure to other decongestants in the same trimester. The reference group for all analyses was subjects unexposed to any decongestant.
Statistical analyses
We assessed specific defects previously reported to be associated with 1 or more decongestants: eye defects, ear defects, ventricular septal defect, coarctation of the aorta, endocardial cushion defect, pyloric stenosis, small-intestinal atresia/stenosis, clubfoot, gastroschisis, and hemifacial microsomia. In addition, for 21 case groups that included at least 100 subjects each, we explored possible risks for other common specific defects.
We estimated separate odds ratios and 95% confidence intervals for each specific birth defect in relation to each specific decongestant by multivariate conditional logistic regression, with calendar year of interview and geographic region of birth hospital as the matching factors to control for the effects of secular trends and regional variations in recruitment of study subjects and exposures. Potential confounders included maternal race/ethnicity; age; prepregnancy weight and body mass index; educational level; smoking; alcohol consumption; diabetes; hypertension; asthma; allergy; first-trimester episodes of convulsions, respiratory infection, and fever; firsttrimester use of acetaminophen, aspirin, ibuprofen, nonaspirin nonsteroidal antiinflammatory drugs overall, antihistamines, cough medications, and antibiotics; periconceptional folic acid supplementation; family income; family historyof birth defects; number of fetuses; planned pregnancy; and number of live births. We adjusted for the potential confounders associated with each specific decongestant and birth defect in our population. For our exploratory analyses, we did not estimate odds ratios for exposures with fewer than 5 exposed cases or controls because of the instability of such estimates.
Because pseudoephedrine is often combined with acetaminophen, and because a previous study that had hypothesized an association with gastroschisis and small-intestinal atresia/stenosis (7) found the highest risk for the combination of pseudoephedrine and acetaminophen, we further stratified pseudoephedrine exposure according to whether it was taken as a single-component product or was combined with acetaminophen. To assess the sensitivity of results to timing of exposure, we carried out separate analyses for second-and third-trimester exposures, restricted to subjects who had not been exposed to the specific decongestant in the first trimester. All analyses were performed in SAS for Microsoft Windows, version 9.2 (SAS Institute Inc., Cary, North Carolina).
RESULTS
Among mothers of nonmalformed infants (n = 7,606), 8.6% of subjects (n = 656) reported taking 1 or more oral or intranasal decongestants during the first trimester. Use of oral products was reported by 7.8% of subjects (n = 592); 7.0% (n = 531) took pseudoephedrine only, 0.4% (n = 28) phenylephrine only, and 0.4% (n = 30) phenylpropanolamine only. Use of intranasal decongestants was reported by 1.2% Table continues 200 Yau et al.
of subjects (n = 92); oxymetazoline was the most common (0.9%, n = 66). Factors associated with first-trimester decongestant use are presented in Table 1 .
Oral decongestants
Assessment of hypothesized associations. For pseudoephedrine and ventricular septal defect (Table 2) , the risk for single-component pseudoephedrine approximated the null (odds ratio (OR) = 1.1, 95% confidence interval (CI): 0.8, 1.5), but use of pseudoephedrine/acetaminophen was associated with an increased risk (OR = 1.8, 95% CI: 1.2, 2.7). Acetaminophen itself did not affect the risk (OR = 1.0, 95% CI: 0.9, 1.2). For phenylephrine, we observed an elevated risk for endocardial cushion defect (OR = 8.0, 95% CI: 2.5, 25.3; 4 exposed cases). All 4 exposed cases had multiple anomalies, including other cardiovascular defects, and 1 had a limb defect. For phenylpropanolamine, we found increased risks of ear defects (OR = 7.8, 95% CI: 2.2, 27.2; 4 exposed cases) and pyloric stenosis (OR = 3.2, 95% CI: 1.1, 8.8; 6 exposed cases). None of the aforementioned associations was observed for second-or third-trimester exposure (Web Table 2 ).
For pseudoephedrine and gastroschisis (Table 2) , use of single-component pseudoephedrine was associated with an increased risk (OR = 3.0, 95% CI: 1.4, 6.2), whereas only 1 gastroschisis case was exposed to pseudoephedrine/acetaminophen; conversely, for small-intestinal atresia/stenosis, single-component pseudoephedrine was associated with a smaller risk than the combination product (odds ratios of 1.4 and 2.3, respectively), but their lower confidence bounds included 1.0. Acetaminophen itself was not associated with gastroschisis (OR = 0.9, 95% CI: 0.7, 1.3) or small-intestinal atresia/stenosis (OR = 1.1, 95% CI: 0.8, 1.5).
For hemifacial microsomia, the total number of cases (n = 47) was too small to allow evaluation.
Our findings did not support most other previously hypothesized associations between first-trimester exposures to specific oral decongestants and specific defects; these include pseudoephedrine and coarctation of the aorta (OR = 1.1, 95% CI: 0.7, 1.8), phenylephrine and eye and ear defects (only 1 exposed case for each defect group) and clubfoot (only 2 exposed cases), and phenylpropanolamine and eye defects and gastroschisis (no exposed cases for either defect).
Exploratory analyses. In our exploratory analyses of exposures and defects not previously hypothesized to be associated with decongestants, there were 84 comparisons of firsttrimester exposure to oral decongestants overall, pseudoephedrine, phenylephrine, and phenylpropanolamine in relation to 21 other specific birth defect groups with at least 100 cases each. These analyses yielded adjusted odds ratio estimates ranging from 0.7 to 2.4 (Table 3) .
Only 1 of these comparisons had lower 95% confidence bounds that exceeded 1.0: pseudoephedrine and limb reduction defects (OR = 2.4, 95% CI: 1.5, 3.7) (Table 3); this Abbreviations: CI, confidence interval; OR, odds ratio. a Not exposed to any decongestant at any time from 56 days before the date of the last menstrual period through the end of pregnancy. b Likely exposed to any decongestant during the first trimester of pregnancy. c Matched on calendar year of interview and geographic region of birth hospital. Odds ratios not estimated for fewer than 5 decongestant users. d Not available because of missing data. e Reference category for each variable is "none during pregnancy," except for diabetes and hypertension, where reference is "never". f Cough medications included antitussives (dextromethorphan, benzonatate), expectorants (guaifenesin, guaiacolsulfonate potassium, ammonium carbonate, iodinated glycerol), and mucolytics (acetylcysteine, carbocysteine).
g Any exposure from 1 month before to 1 month after the estimated date of conception.
Decongestants and Risk of Birth Defects 201 association was not observed for second-or third-trimester exposures (Web Table 2 ). The risk was elevated both for first-trimester use of pseudoephedrine alone (OR = 2.5, 95% CI: 1.4, 4.5) and for pseudoephedrine/acetaminophen (OR = 3.5, 95% CI: 1.7, 7.2). Acetaminophen itself did not affect the risk (OR = 1.1, 95% CI: 0.8, 1.6).
Intranasal decongestants
In our exploratory analyses of first-trimester exposure to intranasal decongestants and defects not previously reported to be associated with intranasal decongestant use, we conducted 150 comparisons that included intranasal decongestants Abbreviations: CI, confidence interval; OR, odds ratio. a Refers to subjects likely exposed to decongestant in first trimester (n = 1,833) among a total of 20,340 subjects. b Hemifacial microsomia was excluded from this table because the total number of cases (n = 47) was too small to allow evaluation. c Not exposed to other decongestants in the first trimester. d All odds ratios and 95% confidence intervals were estimated on the basis of conditional logistic regression matched on calendar year of interview and geographic region of birth hospital. In addition, for each exposure-outcome association, we adjusted for factors associated with the specific decongestant and the specific birth defect in our population that also materially changed the odds ratio estimate, as specified in the following footnotes. Odds ratios were not estimated for fewer than 4 exposed cases.
e Adjusted for first-trimester episodes of respiratory infection and first-trimester use of cough medications. overall, imidazoline derivatives overall, oxymetazoline, xylometazoline, and non-imidazoline derivatives in relation to 30 common specific birth defects with at least 100 cases each. The adjusted odds ratio estimates ranged between 0.7 and 3.3 (Table 4) , with 95% confidence intervals for 2 specific malformations with first-trimester exposure excluding the null. Pyloric stenosis was associated with intranasal decongestants overall (OR = 1.9, 95% CI: 1.0, 3.5), imidazoline Abbreviations: CI, confidence interval; OR, odds ratio. a Refers to subjects likely exposed in first trimester. b Results for first-trimester exposure to phenylephrine only (n = 82) and phenylpropanolamine only (n = 57) are not presented in this table because there were fewer than 5 exposed cases for each specific birth defect, except for phenylephrine and cleft palate alone (adjusted OR = 1.7, 95% CI: 0.6, 4.8; 5 exposed cases; adjusted for first-trimester use of cough medications). c Not exposed to other decongestants in the first trimester. d All odds ratios and 95% confidence intervals were estimated on the basis of conditional logistic regression matched on calendar year of interview and geographic region of birth hospital. In addition, for each exposureoutcome association, we adjusted for factors associated with the specific decongestant and the specific birth defect in our population that also materially changed the odds ratio estimate, as specified in the following footnotes. Odds ratios were not estimated for fewer than 5 exposed cases for exploratory analyses.
e Adjusted for prepregnancy weight, educational level, and first-trimester use of cough medications. f Adjusted for alcohol consumption, allergy, and first-trimester episodes of respiratory infection. g Adjusted for maternal educational level and allergy. h Adjusted for first-trimester use of cough medications. i Restricted to males only. Nonmalformed controls (restricted to males only): n = 3,768. j Adjusted for first-trimester use of acetaminophen and cough medications. k Adjusted for maternal race/ethnicity and allergy. l Adjusted for maternal race/ethnicity and first-trimester episodes of respiratory infection. m Adjusted for first-trimester use of antihistamines and cough medications. Abbreviations: CI, confidence interval; OR, odds ratio. a Refers to subjects likely exposed to decongestant in first trimester (n = 1,833) among a total of 20,340 subjects. b Results for first-trimester exposure to non-imidazoline derivatives only (phenylephrine, levmetamfetamine, propylhexedrine) (n = 31) are not presented in this table because there were fewer than 5 exposed cases for each specific birth defect.
c Results presented in this table are only for specific birth defects with at least 5 exposed cases. d Not exposed to other decongestants in the first trimester. e All odds ratios and 95% confidence intervals were estimated on the basis of conditional logistic regression matched on calendar year of interview and geographic region of birth hospital. In addition, for each exposure-outcome association, we adjusted for factors associated with the specific decongestant and the specific birth defect in our population that also materially changed the odds ratio estimate, as specified in the following footnotes. Odds ratios were not estimated for fewer than 5 exposed cases for exploratory analyses.
f Adjusted for maternal race/ethnicity and educational level. g Adjusted for maternal race/ethnicity. h Restricted to non-neural tube defect cases, so as to exclude cases of clubfoot, which can be secondary to a neural tube defect. i Adjusted for maternal age; educational level; first-trimester episodes of respiratory infection; and first-trimester use of acetaminophen, antihistamines, cough medications, and antibiotics. j Adjusted for maternal educational level and first-trimester use of cough medications. k Restricted to males only. Nonmalformed controls (restricted to males only): n = 3,768.
derivatives (oxymetazoline or xylometazoline) (OR = 2.2, 95% CI: 1.1, 4.5), and specifically xylometazoline (OR = 2.9, 95% CI: 1.0, 7.9) ( Table 4) . None of these associations was observed for second-or third-trimester exposure (Web Table 3 ). The risk of tracheo-esophageal fistula was associated with first-trimester exposure to imidazoline derivatives (OR = 3.3, 95% CI: 1.2, 8.9) ( Table 4 ). This association was not observed for second-or third-trimester exposure (Web Table 3 ).
We also found associations between renal collecting system anomalies and second-trimester exposure to oxymetazoline (OR = 3.1, 95% CI: 1.3, 6.9) (Web Table 3 ).
DISCUSSION
Findings from this case-control study support previously hypothesized associations between first-trimester exposure to phenylephrine and endocardial cushion defect (10) , between first-trimester exposure to phenylpropanolamine and ear defects (9, 11) , and between first-trimester exposure to phenylpropanolamine and pyloric stenosis (11) . In exploratory analyses designed to generate hypotheses, multiple comparisons identified associations between first-trimester use of pseudoephedrine and limb reduction defects, between first-trimester use of intranasal decongestants and pyloric stenosis, and between first-trimester use of imidazoline derivatives and tracheoesophageal fistula, as well as between second-trimester use of oxymetazoline and renal collecting system anomalies.
Forphenylephrine, the increased riskof endocardial cushion defect identified in a previous case-control study (OR = 6.7, 90% CI: 1.3, 26; 2 exposed cases) (10) was replicated in our study (OR = 8.0, 95% CI: 2.5, 25.3; 4 exposed cases). Of note, phenylephrine belongs to the same class of substituted phenethylamines as fenfluramine and dexfenfluramine, which were associated with cardiac valvulopathy in adult users (21) . All 3 compounds share the 2-phenylethylamine chemical structure.
For phenylpropanolamine, the US Collaborative Perinatal Project found an elevated risk of eye and ear defects (as a single group) (relative risk = 4.0, 95% CI: 1.6, 8.3) (9), and a more recent Swedish Register study identified a modest association for ear defects (relative risk = 1.7, 95% CI: 0.8, 3.2) but not for eye defects (relative risk = 0.8, 95% CI: 0.1, 2.7; 2 exposed cases) after exposure to "oral decongestants" (99% exposed to phenylpropanolamine and 1% pseudoephedrine) (11) . We also observed an increased risk of ear defects (OR = 7.8, 95% CI: 2.2, 27.2; 4 exposed cases) but not eye defects (no exposed cases) after first-trimester phenylpropanolamine exposure. We also replicated the association between pyloric stenosis and phenylpropanolamine (OR = 3.2, 95% CI: 1.1, 8.8; 6 exposed cases) that was reported in the same Swedish study (relative risk = 2.4, 95% CI: 0.9, 6.4; 4 exposed cases) (11) .
Although the elevated risks that we observed on the basis of relatively small numbers for endocardial cushion defect and first-trimester exposure to phenylephrine, as well as ear defects and pyloric stenosis in relation to phenylpropanolamine, could be due to chance, these findings were observed in the context of testing specific hypotheses raised by others (9) (10) (11) . Furthermore, our assessment of confounding included illnesses that might represent confounding by indication. Controlling for factors other than those that we included in our multivariate models did not substantially influence our results. As with all observational studies, retrospective reporting of maternal conditions in the first trimester (e.g., respiratory infection, fever) might be inaccurate, and residual confounding by uncontrolled factors cannot be ruled out.
Previous investigations of gastroschisis risks by our group, including 1 study that included a subset of the cases reported here (7), identified 1.8-fold (7) and 3.2-fold (5) odds ratios associated with any pseudoephedrine use in early gestation. Our present analysis of women who were most likely to be exposed in early gestation provided weak support for such an association, with a 1.5-fold odds ratio and a lower 95% confidence interval of 0.8. However, when we separated pseudoephedrine exposures into single-component pseudoephedrine versus pseudoephedrine/acetaminophen, the pattern of odds ratios was opposite that in the earlier study (7): We found an elevated risk for gastroschisis with the use of singlecomponent pseudoephedrine (OR = 3.0, 95% CI: 1.4, 6.2), but only 1 gastroschisis case was exposed to the combination product. Our findings for first-trimester pseudoephedrine and small-intestinal atresia/stenosis were compatible with an earlier report by our group (7); in the present analyses, we similarly observed a moderately increased risk for overall use (OR = 1.6, 95% CI: 0.9, 2.8) that was higher for pseudoephedrine/acetaminophen (OR = 2.3, 95% CI: 0.9, 6.1) than for single-component pseudoephedrine (OR = 1.4, 95% CI: 0.6, 3.1).
Our findings did not confirm other reported associations. Although a previous study found a 2.4-fold risk of ventricular septal defect with first-trimester exposure to oral decongestants (95% CI: 0.9, 6.3) (3), we found an odds ratio of only 1.3 (with a narrow 95% CI: 1.1, 1.6) for exposure to oral decongestants overall (mainly pseudoephedrine). Of note, we found the risk to be elevated only with pseudoephedrine/acetaminophen (OR = 1.8, 95% CI: 1.2, 2.7) and not with single-component pseudoephedrine (OR = 1.1, 95% CI: 0.8, 1.5). This finding is remarkably consistent with differences previously observed by our group for both gastroschisis and small-intestinal atresia in relation to use of pseudoephedrine/acetaminophen compared with either pseudoephedrine or acetaminophen alone (7) . In other comparisons, we found little support for associations between first-trimester exposure to sympathomimetics (predominantly pseudoephedrine) and coarctation of the aorta (4), first-trimester exposure to phenylpropanolamine and gastroschisis (6) , and first-trimester exposure to phenylephrine and eye and ear defects (9) and clubfoot (9) .
Results from our exploratory analyses corroborated previous reports describing no associations between first-trimester exposure to oral decongestants and neural tube defects (12) , hypospadias (9), or inguinal hernia (9) . We also did not find any appreciable association between first-trimester oral decongestant exposure and other specific birth defects, with the exception of a 2.4-fold increased risk of limb reduction defects with pseudoephedrine.
Understanding the risks associated with phenylephrine is important given the recent trends in use (Figure 1 ). Although pseudoephedrine is still the most commonly used decongestant, the relative use of phenylephrine increased after federal restrictions of access to pseudoephedrine (22) , which also led to the replacement of pseudoephedrine with phenylephrine in some cough/cold preparations. Phenylpropanolamine use has declined as a result of its removal from the market in 2000-2001, which was due to its reported risk of hemorrhagic stroke in adults (23) .
We believe ours is the first study to explore the risks and relative safety of specific intranasal decongestants used during pregnancy with regard to a wide range of specific birth defects. Inasmuch as the analyses on intranasal decongestants were exploratory in nature, the associations we found warrant cautious interpretation because they were identified in the context of no preexisting hypotheses and multiple comparisons; the latter might result in confidence intervals that could be wider than we estimated. However, we believe that the observed elevated risks of 2 malformations warrant further exploration: pyloric stenosis in relation to first-trimester exposure to intranasal decongestants, and tracheo-esophageal fistula in relation to first-trimester exposure to imidazoline derivatives. In addition, renal collecting system anomalies potentially could be associated with second-trimester exposure to oxymetazoline.
It is not known whether any of the oral decongestants (pseudoephedrine, phenylephrine, and phenylpropanolamine) cross the placenta (24) to exert any direct effect on the fetus. Nonetheless, their vasoconstrictive properties as a result of α-adrenergic stimulation could cause constriction of uterine vessels that appear to have only α-adrenergic receptors (25) , potentially contributing to the risk of teratogenicity via vascular disruption or hypoxia-induced oxidative stress (26) . Although administered intranasally for an intended localized effect and generally thought to carry less risk than systemically administered agents, intranasal decongestants, mainly oxymetazoline and xylometazoline, are absorbed well from the nasal mucosa to produce systemic effects (24) . Though it is not known whether these agents cross the placenta (24), a report of fetal heart rate changes after maternal use of oxymetazoline nasal spray (27) suggests that oxymetazoline and possibly other intranasal decongestants could affect the fetus. In addition to their vasoconstrictive α-adrenoceptor agonistic activity (28) , oxymetazoline and xylometazoline are also agonists of some 5-hydroxytryptamine (serotonin) receptor subtypes (29, 30) . Increased stimulation of 5-hydroxytryptamine receptors could potentially affect fetal development and cause birth defects via 5-hydroxytryptamine receptor-mediated teratogenesis (26) .
In its collection of medication histories, the BDS specifically asks about the use of OTC products, providing the opportunity to study this type of drug exposure. Such analyses are not typically possible with other types of data sources, such as claims or pharmacy dispensing databases, which do not routinely capture OTC exposures. Moreover, by relying on maternal report, the BDS focuses on actual use of medications (rather than prescription or dispensing). However, given that information about medication use is obtained retrospectively, the potential for imperfect recall is a concern, particularly the recall of OTC medications (such as decongestants) that tend to be used infrequently and for short durations. In the BDS, the use of a multilevel, highly structured questionnaire (19) and a Medication Identification Booklet with OTC medication photographs likelyenhanced recallof medication exposures. Inaddition, the detailed medication exposure information collected by the BDS allowed us to distinguish subjects who were considered likely exposed (i.e., with high certainty of exposure) (20) from those who were possibly exposed. By creating separate categories instead of combining them into a single group of any potentially exposed subjects, we sought to minimize exposure misclassification. We further focused on subjects who likely had been exposed to only a specific decongestant, without other decongestants in the same trimester; this allowed us to clearly distinguish the specific decongestants that might be associated with specific birth defects. Although this approach could have less power than others that aggregate all potentially exposed subjects, we believe it offers greater validity by reducing exposure misclassification.
In our retrospective interview-based study, recall bias might be a concern if mothers of malformed infants recalled or reported prenatal medication use differently from mothers of nonmalformed controls. That we identified different effect estimates for different decongestants suggests that recall bias was of little relevance, because there is no reason to postulate that women would be biased in their recall of different decongestants in relation to different defects.
Our findings should be kept in perspective. As one example, the baseline prevalence of endocardial cushion defect is about 0.34 per 1,000 live births (31); thus, even if phenylephrine exposure increased the risk 8-fold, the absolute risk of having an affected child still would be small (about 2.7 per 1,000 live births; i.e., 0.27%).
In summary, our data support some previously reported associations and raise a small number of new hypotheses. Given the widespread use of decongestants by pregnant women, there is continuing need to obtain further data on the risks and relative safety of specific decongestants in relation to the wide range of specific birth defects.
